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1. Introduction  
Drug development is a complex process that includes drug discovery/product 
development, pre-clinical research (in vitro/in vivo) and clinical trials. The new chemical 
entities, which show promising pharmacodynamic activity in in vitro experiments on 
particular biological targets, thought to play critical pathophysiological roles in specific 
diseases, emerge from the process of drug discovery and are candidates to undergo safety 
and toxicity tests, as well as pharmacokinetic and metabolism evaluations in in vivo pre-
clinical models. Moreover, pre-clinical investigations are focused on determining the dose 
and administration schedule to be used in the first human clinical trial (first-in-man or first 
human dosing). 
Clinical drug development is currently arranged into four phases, with phase I traditionally 
representing the very early stage of drug development in humans. Phase I is conducted to 
establish safety and tolerability, to evaluate pharmacokinetics and to obtain preliminary 
data on pharmacodynamics. Phase I begins with the first administration of a new compound 
in humans (Pocock, 1983). 
Based on differences in the experimental design, various types of phase I trials can be 
distinguished: (1) Single ascending dose studies, in which small groups of subjects receive a 
single dose of the test drug, afterward they are observed and examined for a given period of 
time. If subjects do not experience any remarkable adverse effect, and pharmacokinetic data 
are roughly consistent with pre-specified safety values, the dose is escalated up, and a new 
group of subjects is then given a higher dose (Buoen et al., 2005). This stepping-up dose is 
continued until the pre-calculated pharmacokinetic safety levels are achieved, or intolerable 
side effects occur, indicating the point at which the drug appears to have reached the 
maximum tolerated dose (Friedman et al., 1996). The first dose to be tested in phase I is 
estimated as a fraction of the so called “no adverse effect dose”, which is the highest dose 
found not to harm animals under appropriate toxicity/safety testing. (2) Multiple ascending 
dose studies, characterized by an experimental design similar to single ascending dose 
studies, with the exception that, at each step, a small group of subjects undergoes repeated 
administration of the same dose of the test drug. Such studies can be conducted to better 
understand the pharmacokinetics and pharmacodynamics of the new drug at the steady 
state. (3) Short trials, designed to investigate variations in the absorption of the new drug 
following its oral administration in the presence of food. 
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The increasing cost of novel drug development, in conjunction with ethical considerations 
about the safety of first-in-man trials, has fostered the implementation of novel procedures 
with the purpose of optimizing, rationalizing, and enhancing the ability of eliminating 
redundancies in early phase clinical trials without compromising safety. Accordingly, a new 
procedure, designated as “phase 0”, has been introduced into the very early stage of clinical 
drug development in order to gain insight into the clinical suitability of novel compounds 
before starting conventional phase I trials (EMEA, 2004; Pasqualetti et al., 2010). 
Additional clinical studies, which are conducted in healthy volunteers, include 
bioequivalence pharmacokinetic tests. To assess bioequivalence between two medicinal 
products containing the same active ingredient, such as a commercially available brand 
product and a generic formulation under clinical development, cross-over pharmacokinetic 
studies in healthy volunteers are currently regarded as the most suitable experimental 
approach (Del Tacca et al., 2009). Furthermore, bioequivalence studies are performed in 
healthy volunteers during pre-registrative development phases, in order to assess different 
formulations of the new active ingredient. 
The present chapter focuses on issues concerning the enrollment of healthy volunteers in the 
early clinical phases of drug development from different points of view, including 
regulatory, methodological, normative, ethical, and logistical perspectives.  
2. Healthy volunteers in early clinical studies 
Defining a healthy volunteer is not an easy task, since different criteria, underlying the 
concept of wellness, can be implied in this condition. The Royal College of Physicians has 
defined the healthy volunteer as an “individual who is not known to suffer of any 
significant illness relevant to the proposed study, who should be within the ordinary range 
of body measurements, such as weight, and whose mental state is such that he is able to 
understand and give valid consent to the study” (Royal College of Physicians, 1986). 
Moreover, in the Association of the British Pharmaceutical Industry guidelines for medical 
experiments in human volunteers, it is highlighted that the individual cannot be expected to 
receive therapeutic benefit from the proposed study (Association of British Pharmaceuticals 
Industries, 1988). The EMEA guideline proposes also a general definition of healthy 
volunteer for studies aimed at assessing pharmacokinetics: “healthy, adult volunteers, in 
well-defined and controlled conditions” (EMEA, 1998). On this basis, the selection of healthy 
volunteers is conducted by enrolling subjects without relevant pathologies and with organ 
functions, such as heart, liver and kidney, in the normal range. However, the general 
definitions of healthy volunteer, as those proposed by current guidelines, allow wide 
margins of discretion. For example, might an asymptomatic subject with allergic rhinitis or 
affected by knee swelling be considered eligible for a phase I clinical experimentation of a 
new antidepressant drug? Furthermore, might women under treatment with oestrogen 
derivatives be eligible for early phases of drug experimentation? These simple examples 
support the notion that we can use different definitions of healthy subjects and that a critical 
judgment is required (Pasqualetti et al., 2010). 
3. Enrollment procedures 
From the industry standpoint, recruitment problems translate into potential revenue losses 
resulting from delays in bringing a new drug into the market (Harris et al., 2005). 
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Accordingly, clinical research units must ensure a fast recruitment of healthy volunteers into 
phase I studies, since an inadequate enrollment may increase the study costs, delay the time 
to completion, and possibly invalidate the trial outcome due to insufficient study power. 
Recruiting volunteers is an unavoidable, often time-consuming, and difficult task in clinical 
research (Bramstedt, 2007). Clinical pharmacological units may overcome recruiting 
problems by facilitating the access of healthy volunteers to information about clinical 
experimentation. Internet advertising of clinical research studies can be accomplished in 
various ways, including websites dedicated to specific studies, clinical trial databases, which 
store basic information about studies, and direct e-mail solicitation to target populations. 
The U.S. Food and Drug Administration (FDA) requires that institutional review boards 
(IRB) examine and approve the advertising materials and methods used to recruit human 
subjects. Additionally, FDA has issued a guidance regarding internet advertising. In 
particular, FDA does not require IRB to review internet listings of clinical trials as long as 
the listings provide only “basic trial information” (e.g., study title, study summary, study 
location, contact information). Internet databases, which are designed with formal system 
limits (e.g., font size, font style, entry of only basic study information), satisfy this guidance, 
and thus, do not require IRB approval for each study listing. Bramstedt (2007) analyzed the 
incidence and nature of ethically inappropriate recruiting advertisements on internet, and 
provided a descriptive guidance to clinical investigators for responsible internet recruiting. 
The majority of advertisements satisfied the FDA guidance. However, 18% of them were 
ethically questionable with regard to font size, font style, and/or verbiage. This author 
concluded that inappropriate recruiting advertisements can be coercive and misleading. 
4. Pharmacokinetic and pharmacodynamic investigations 
Clinical pharmacokinetic studies are performed to examine absorption, distribution, 
metabolism, and excretion patterns of investigational or approved drugs in healthy 
volunteers and, where appropriate, in patients. Data obtained from early pharmacokinetic 
testing are useful for designing and conducting extensive clinical trials. Pharmacokinetic 
studies are also necessary in the post-marketing setting for bioequivalence assessments (Del 
Tacca et al., 2009). Moreover, clinical pharmacokinetic studies are also relevant for 
determining the appropriate use of medicines in particular populations, mainly in patients 
with impaired renal or liver function, for predicting the outcome of pharmacokinetic drug 
interactions and for assessing genetic variants in drug metabolism. Data on drug 
concentration-time profiles, obtained from clinical trials, can also provide information for 
therapeutic drug monitoring in clinical practice.  
In a single-dose study, the concentrations of an investigational drug and its metabolites are 
measured in blood samples following a single administration to healthy volunteers and/or 
patients. Furthermore, the levels of the investigational drug and its metabolites in blood, 
urine and, when necessary, faeces are measured to evaluate the elimination pathways. Drug 
binding to plasma proteins, time-concentration profiles, and the effects of meals on its 
bioavailability should also be investigated in single-dose studies. In order to evaluate the 
relationship between the dose and the respective pharmacokinetic profiles, several doses 
should be tested. Some pharmacokinetic studies, both in healthy volunteers and patients, 
aiming at evaluating not only the relationship between dose and blood concentrations, but 
also that between pharmacological effects and blood levels, may provide valuable 
information for future clinical development. 
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As far as pharmacodynamic investigations during a clinical trial are concerned, drug effects 
can be studied both with hard endpoints, like the patient survival, or surrogate endpoints. A 
surrogate endpoint (or marker) is an effect measure of a certain treatment that may correlate 
with a real clinical outcome, but doesn't necessarily have a firm relationship with it. The US 
National Institutes of Health define a surrogate endpoint as "a biomarker intended to 
substitute a clinical endpoint” (Cohn, 2004).  
Several authors have suggested the use of biomarkers as a method for obtaining early 
indications of drug effectiveness and safety, both for research and regulatory approval 
purposes, thereby reducing costs and development time (Frank & Hargreaves, 2003; FDA, 
2004). Indeed, it has been estimated that small improvements in clinical trial outcomes and 
decision-making translate into hundreds of million dollars of development cost-savings and 
a faster time-to-market (DiMasi, 2002). Therefore, the use of biomarkers is encouraged to 
such an extent that they are routinely examined as a part of many new drug trials. 
The traditional gold standard for evaluating drug safety and efficacy relies on prospective, 
randomized, well controlled, double-blind clinical trials (Merrill, 1996). Although this 
paradigm has served well the public health in ensuring that new drugs are thoroughly and 
scientifically evaluated before reaching the consumer, some investigators have argued that 
reliance on morbidity and mortality data – the so-called ‘true endpoints’ – could have had 
the unintended consequence of contributing to the high cost of pharmaceutical innovations. 
In an attempt of avoiding such cost increments, with the enactment of the FDA 
Modernization Act of 1997, the FDA was given explicit authority to approve drugs for the 
“treatment of a serious or life-threatening condition…upon a determination that a product 
has an effect on a clinical endpoint or on a surrogate endpoint that is reasonably likely to 
predict clinical benefit”. 
Traditional biomarkers, such as analytes assayed in serum, have been employed for decades 
in the clinical practice and drug development. However, a variety of new biomarkers have 
recently fostered great interest. In particular, the use of imaging biomarkers for the 
assessment of drug therapies – a field designated as “pharmaco-imaging” – has become very 
common in recent years. Not surprisingly, the rise in use of pharmaco-imaging 
methodologies has coincided with the impressive technical advances occurred in medical 
imaging, with particular regard for noninvasive in vivo imaging methodologies such as 
computerized tomography (CT), magnetic resonance imaging (MRI) (Rudin et al., 1999; 
Beckmann et al., 2004) and positron emission tomography (PET) (Fischman et al., 2002; 
Gambhir, 2002). 
Several characteristics of imaging biomarkers differentiate them from traditional 
biomarkers. First, non-invasive imaging has been applied routinely to diagnosis and disease 
management for several decades, and the ability to identify a wide spectrum of 
pathophysiological conditions by means of imaging techniques is well established. Second, 
imaging biomarkers tend to be more closely associated with disease phenotypes, thus 
enabling a direct association between therapy and its effect. Third, imaging allows a marked 
versatility in providing continuous, structural and functional assessments of therapy, thus 
offering snapshots of drug bioactivity over time (Pien et al., 2005).  
5. Efficacy-related surrogate endpoints 
Several techniques can be used to measure indirectly the effect of drugs in healthy 
volunteers (Passchier et al., 2002). Currently, drug dosing regimens for patients are based 
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mainly on the outcome of preclinical and phase I–II human studies, such as in vitro 
autoradiography, dose–effect relationships, plasma concentration, tolerability, 
electroencephalography (EEG), and functional MRI (fMRI) or PET. Although these 
measurements have their own merits, they cannot provide direct insight into the 
relationship between the amount of drug administered and the occupancy of its target, thus 
not allowing a correlation of the results with the effectiveness of the drug in treating the 
disease. For example, a drug that is assumed to exert its action on the central nervous 
system (CNS) may instead induce a systemic release of endogenous factors, such as cortisol 
or noradrenaline, thus leading to changes in EEG patterns or changes in cerebral blood flow, 
which can be misinterpreted as the drug having a direct effect on CNS. Likewise, measuring 
drug plasma levels following single or repeated administration, and assuming that target 
occupancy is linearly related to the dose or plasma concentration, may be incorrect.  
Two cases can be easily identified in which plasma concentration does not reflect the actual 
target occupancy. First, if brain uptake is high and the drug off-rate from its target is slow, a 
significant fraction of the target receptor will remain occupied for prolonged periods, even if 
the clearance of the drug from plasma is rapid. Second, a drug can be effective on CNS, even 
if it shows a very little brain uptake and, consequently, a very low target occupancy. 
(Sawada et al., 1991; Gibson et al., 2000). 
Two techniques are currently available to provide a direct measurement of drug-related 
receptor occupancy. PET and single-photon emission computed tomography (SPECT) both 
use radiolabelled ligands specifically designed to bind the desired target with high 
selectivity and specificity. Although SPECT has certain advantages, such as a relatively long 
half-life of radionuclides, it displays also major drawbacks, including low sensitivity, 
limited temporal resolution, impossibility of labelling the native drug since its conjugation 
with 99mTc, 131I, and 111In may result in changes in its chemical properties (Sawada et al., 
1991; Gibson et al., 2000). 
Although various issues, concerning the study design and data interpretation, must be taken 
into account, PET can play a relevant role in the evaluation of novel drugs. Imaging studies 
may demonstrate whether the drug reaches its target, if there is a linear relationship 
between dose and target occupancy, if the occupancy reflects plasma drug levels, and how 
long the drug remains bound to its target. PET data from healthy volunteers can thus 
provide very useful information for the design of early clinical trials (Passchier et al., 2002). 
5.1 Use of biomarkers in neuroscience 
Treatment of neuro-degeneration or CNS diseases has been a daunting task, and therefore, 
substantial efforts have been made to identify and validate biomarkers to support the 
implementation of effective therapies (Bakhtiar, 2008). Notably, understanding the 
molecular bases of Alzheimer's and Parkinson's disease, and identifying novel brain 
molecular targets has been subject to intense research and high investment by industry, 
government, and academia. Examples of methodologies employed to identify biomarkers in 
CNS include brain imaging techniques such as PET, CT, MRI and SPECT. In addition, facial 
expression recognition task, Visual Analogue Mood Scale, anxiety tests, genetic markers, 
catecholamine concentrations, psycho-immunological markers, and neuroendocrine 
markers are among other complementary approaches (Bieck & Potter, 2005). Since drugs 
that directly target CNS receptors must show good permeability across the blood–brain 
barrier (BBB) and sufficient brain exposure, an approach is needed to determine the extent 
of receptor occupancy, which is defined as the percent of receptor population that is 
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occupied by the drug at a specific dose or concentration in plasma. The data obtained from 
such imaging biomarkers are then correlated with the pharmacokinetic data to generate a 
pharmacokinetic/pharmacodynamic (PK/PD) model, understand the mechanism of action, 
select the most promising compounds candidate to clinical development, guide dose 
selection, and/or develop predictive tools at early stages of clinical development (de Boer & 
Gaillard, 2007). There are two common approaches for obtaining information on BBB 
penetration: to apply an imaging technique (non-invasive); to sample cerebrospinal fluid 
directly from the central compartment (invasive). Recent advances in medical imaging have 
made it possible to employ PET in order to detect picomolar levels of radiolabelled drugs in 
both preclinical models and humans (Frank & Hargreaves, 2003; Lee & Farde, 2006). 
5.1.1 Magnetic resonance imaging and pharmaco-MRI 
In contrast with the use of ionizing radiations in CT, MRI employs radio-frequency pulses 
and magnetic fields to obtain signals from changes in nuclear magnetic moments (Pien et al., 
2005). In particular, as the alignment and relaxation of protons occur in response to pulsed 
radio-frequencies, characteristic relaxation times can be measured, most notably T1 
(longitudinal relaxation time) and T2 (transverse relaxation time) (McRobbie et al., 2002). 
While CT images result from a single parameter, namely the X-ray attenuation by the tissue 
along the propagation path, MRI is generated by multiple parameters, including proton 
density, T1, T2, flow, diffusion and susceptibility. MRI is useful for several applications, 
including central and peripheral nervous system function and visualization, both under 
basal conditions and after environmental stimuli. 
Although MRI displays lower resolution and requires a longer time for data acquisition than 
CT, the former offers higher soft tissue contrast, thus making MRI the technique of choice in 
the brain, besides specific applications in musculoskeletal and gastrointestinal systems. MRI, 
with or without the aid of contrast agents, is also employed for a number of functional 
assessments, including tissue perfusion, tumour permeability, and blood oxygenation level-
dependent (BOLD) studies (Le Bihan, 1995; Sorensen & Reamer, 2000). 
Pharmaco-MRI allows in vivo visualization of human brain activity and enables non-
invasive assessments of drug-related changes in this activity (Windischberger et al., 2010). 
Several studies have investigated the effects of antidepressant drugs, such as selective 
serotonin reuptake inhibitors (SSRIs) on neural activation (Anderson et al., 2008; Arce et al., 
2008), indicating area-specific and dose-dependent effects on the BOLD response in both 
healthy subjects (Loubinoux et al., 2002; Del-Ben et al., 2005) and patients suffering from 
major depression and obsessive–compulsive disorder (Hoehn-Saric et al., 2004). These 
effects were particularly pronounced in the amygdala, the key brain region in processing 
and consolidating aversive emotional cues. For instance, a study on acute citalopram 
administration in twelve healthy male volunteers showed an increased BOLD signal in 
those brain areas typically involved in depression (McKie et al., 2005). 
5.1.2 Positron emission tomography and single-photon emission computed 
tomography  
The basis of radionuclide imaging is the use of bi-functional compounds containing a 
radiolabelled moiety, which confers detectability, and a chemical and/or pharmaceutical 
moiety, which determines uptake and distribution throughout the body. In the case of 
positron-emitting radioisotopes, the emitted positron passes through tissues and is 
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ultimately annihilated upon combination with an electron, resulting in two photons emitted 
in opposite directions. Detectors are arranged in a ring around the tissue of interest, and 
only triggering photonic stimuli arriving near simultaneously at diametrically opposite 
detectors can be recorded. Tomographic methods are then used to construct the resulting 
PET images. Several radioisotopes are used for nuclear imaging. These tracer isotopes can 
be substituted directly into drug compounds to mimic naturally occurring compounds, or 
can be conjugated with other molecules to form new compounds referred to 
radiopharmaceuticals. 2-18Fluoro-2-deoxy-D-glucose (FDG), for example, is an analogue of 
glucose labelled with a positron-emitting form of fluorine, and it is used in PET imaging of 
metabolic activities that involve glucose uptake (Gambhir, 2002).  
In the case of investigations concerning the dopaminergic system, other iodine radiolabelled 
compounds can be employed (e.g., [123I] FP-CIT: N-ω-fluoropropyl-2β-carbomethoxy-3β(4-
iodophenyl)tropane) (Figure 1).  
 
 
Fig. 1. Transversal sections of [123I]FP-CIT SPECT from brain of a normal subject (left) and a 
patient affected by PParkinson’s disease (right). Radiolabelled compound pattern shows a 
reduced uptake, both in putamen and caudatum, associated with the degeneration of 
nigrostriatal nerve fibers (by courtesy of Prof. G. Mariani, Nuclear Medicine Unit, 
University of Pisa) 
It is this diversity in imaging capabilities that allows imaging biomarkers to address a 
spectrum of drug development issues (Pien, 2005). 
The utility of PET studies in healthy volunteers could be represented by drug effect 
evaluation in specific cerebral areas, in terms of receptor occupancy. In the study by Smith 
and colleagues (2007), the receptor occupancy produced by treatment with mirtazapine 
differed significantly among brain regions, showing that higher receptor occupancies were 
achieved by 7.5 and 15 mg of mirtazapine in high-binding regions (e.g., cortex, amydgala 
and hippocampus) than in regions with less binding properties (e.g., thalamus and 
putamen). Thus, PET studies of regional receptor occupancy using [11C]mirtazapine may 
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provide a reliable mean for testing hypotheses concerning the role of central alpha2-
adrenergic dysfunctions in psychiatric disorders (Smith et al., 2007). 
5.1.3 Pharmaco-EEG studies of psychotropic drugs  
EEG can detect with high sensitivity functional alterations of human brain. Specific EEG 
patterns related to various psychotropic drugs, such as antipsychotics, antidepressants, 
anxiolytics, psychostimulants and nootropics, have been reported (Mucci et al., 2006).  
By a combination of computer-assisted quantitative analyses of EEG with statistical 
procedures (quantitative pharmaco-EEG) and mapping techniques (pharmaco-EEG 
mapping), Saletu and colleagues (2005) classified psychotropic substances and indirectly 
evaluated their bioavailability in the human brain. In particular, by means of pharmaco-EEG 
techniques it is possible to determine, at an early stage of drug development, whether a 
drug is effective on CNS as compared with placebo, what clinical efficacy will be likely 
achieved, at which dosage it acts, when it acts and equipotent dosages of different galenic 
formulations. Pharmaco-EEG patterns and maps of neuroleptics, antidepressants, 
anxiolytics, hypnotics, psychostimulants and nootropics/cognition-enhancing drugs differ, 
and these differences could reflect the influence of several factors, such as acute or chronic 
drug administration or differences between normal subjects and patients. Pharmaco-EEG 
evaluations of these drug classes could anticipate their effects on CNS, their PK/PD profiles 
and their therapeutic efficacy.  
Saletu et al. (2002) investigated the relationship between alterations induced by mental 
disorders and psychotropic drugs by means of an EEG source analysis, designated as low-
resolution brain electromagnetic tomography. Through this approach, they found that some 
neuroleptics, antidepressants, anxiolytics, hypnotics, psychostimulants and 
nootropics/cognition-enhancing drugs exerted EEG effects which appeared to counteract 
the EEG changes associated with mental disorders (i.e., schizophrenia and generalized 
anxiety disorder). Such a phenomenon has been termed “key–lock principle”. In line with 
this principle, Yoshimura et al. (2007), who performed a placebo-controlled pharmaco-EEG 
study on two conventional antipsychotics (chlorpromazine and haloperidol) and four 
atypical antipsychotics (olanzapine, perospirone, quetiapine and risperidone) in healthy 
volunteers, observed that, under perospirone and haloperidol, the EEG pattern was 
opposite as compared with the pattern previously reported in schizophrenic patients, thus 
suggesting a key–lock mechanism. 
A compatibility or incompatibility with the key–lock hypothesis does not necessarily have 
implications for the effectiveness of the drug, but rather for the potential mechanisms of 
action. Indeed, a key–lock pattern of drug response suggests that the drug acts upon 
bioelectrical processes that are present both in patients and healthy controls, although in 
patients such processes are quantitatively different, thus suggesting functional alterations 
(Yoshimura et al., 2007). 
5.1.4 Facial expression recognition task  
The area-specific and stimulation-dependent changes in human brain activation by SSRIs 
are important issues for improving our understanding of the mechanisms evoked by 
pharmacological treatments. For instance, dysfunctions of the emotion processing circuitry 
are associated with depression and anxiety disorders (Akimova et al., 2009), and SSRI-
induced changes in reactivity within this circuitry can be taken as indicators of treatment 
response and efficacy (Anderson et al., 2008; Cipriani et al., 2009). In particular, it has been 
www.intechopen.com
 Drug Experimentation in Healthy Volunteers 
 
569 
suggested that, under SSRI treatment, the decrease in clinical symptoms can depend on 
changes in the processing of emotional stimuli (i.e., enhanced positive emotion processing in 
concomitance with an attenuated negative emotion processing) (Nathan et al., 2003). 
Several studies have shown that changes in serotonin neurotransmission can modulate the 
identification of emotional faces, particularly fearful faces. Alves-Neto and colleagues (2010) 
performed their studies on healthy volunteers by using faces from the Pictures of Facial 
Affect Series, portraying six basic emotions (anger, disgust, fear, happiness, sadness, and 
surprise), which had been morphed to range from neutral (0%) to a standard emotion 
(100%), in 10% steps of emotion intensity. For each emotion, pictures of 2 males and 2 
females were presented at each intensity level, thus comprising 40 stimuli for each emotion. 
The faces were displayed in the computer screen for 0.5 s, with an interval (blank screen) of 
4.5 s among the various stimuli. Volunteers were requested to select the response that best 
described the emotion shown in the picture and to record their responses as soon as possible 
by pressing one of the labelled keys on the keyboard. A single oral dose of escitalopram (10 
mg) or placebo was administered to healthy male volunteers 3 hours before testing the 
Facial Affect Series. Escitalopram facilitated the recognition of sadness and inhibited the 
recognition of happiness in male, but not female, faces. These results confirm that serotonin 
modulates the recognition of emotional faces, and suggest that the gender of the face subject 
can play a role in this modulation (Alves-Neto et al., 2010). Based on these findings, the 
facial expression recognition test represents an innovative model suitable for studying old 
and new antidepressant drugs in healthy volunteers. 
5.1.5 Biomarkers for antipsychotic drugs  
Studies of novel antipsychotics in healthy volunteers deal traditionally with 
pharmacokinetics and tolerability, but useful information can be also obtained from 
biomarkers of clinical endpoints. A reliable biomarker should meet the following 
requirements: consistent response across studies of different antipsychotics; clear response 
of the biomarker to a therapeutic dose; dose-response relationship; plausible relationship 
among the biomarkers, pharmacology and pathogenesis (Figure 2). 
A review by de Visser and co-workers (2001) has identified 65 studies investigating the 
effects of 23 neuroleptics by means of 101 different neuropsychological tests, which could be 
clustered into seven neuropsychological domains. Subjective and objective measures of 
alertness, as well as those of visual-visuomotor-auditory and motor skills were most 
sensitive to antipsychotics, although over half of studies failed to show significant 
differences from placebo (de Visser et al., 2001). With regard for the subjective assessments, 
most individual analogue scales, in order to assess alertness, mood and calmness, have been 
proposed and applied to the evaluation of psychotropic drugs. Other scales can be used to 
examine anxiety, subjective psychotropic drug effects and extrapyramidal side effects 
(Norris, 1971; Bond et al., 1974). 
In addition to EEG, as discussed above, other valid tools can be used for psychological and 
neurological assessment of novel drugs in healthy volunteers. Smooth pursuit and saccadic 
eye movements have been extensively validated to assess the side effects of psychotropic 
drugs. These effects are not specific for a class of drugs (van Steveninck, 1993), but they 
rather allow to quantify sleep/wake transitions. For instance, schizophrenic patients display 
abnormalities in stimulation-related potentials, which are postulated to reflect characteristic 
changes in the stimulus discriminability and decision making. Typically, these changes 
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consist of a reduction in the amplitude and a prolongation in the latency of the P300 
component of evoked potentials. 
 
 
Fig. 2. Features and usefulness of reliable biomarkers and their investigational and clinical 
application targets. PK/PD: pharmacokinetic/pharmacodynamic relationship  
Increments of serum prolactin response in healthy volunteers reflect the “therapeutic” 
antidopaminergic effect of antipsychotic drugs, while changes in growth hormone and 
cortisol secretion are studied as biomarkers for antipshycotic activity of drugs on the 
serotoninergic system. The most consistent effects have been associated with prolactin 
increase, where 96% of all studies reviewed by deVisser et al. (2001) showed statistically 
significant effects. 
5.2 Biomarkers for anti-inflammatory drugs  
Endotoxin or lipopolysaccharide (LPS) (Thorn, 2001; Kharitonov & Sjöbring, 2007) is a 
component of the outer cell wall of Gram-negative bacteria. LPS is a highly potent pro-
inflammatory substance, which, upon inhalation, causes fever, chills and 
bronchoconstriction in a dose-dependent fashion. These symptoms are accompanied by a 
pro-inflammatory response, detectable in sputum and bronchoalveolar lavage fluid as 
elevation of neutrophils, macrophages and certain cytokines/chemokines. Such a response 
can be partly modified by specific drugs.  
There is increasing evidence that diseases caused by organic dusts are mainly inflammatory 
in nature. Among the several agents found in organic dusts, LPS is a major candidate for the 
Reproducibilty, specificity and 
sensibilty of analytical 
methodologies 
 
Plausible relationship among 
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pathophysiological process 
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pathogenesis of inflammatory reactions. Consistently with this view, the inhalation of LPS 
increases neutrophils, lymphocytes and fibronectin levels in the bronchoalveolar lavage 
fluid from healthy volunteers (Sandström et al., 1992). Changes in mediators of 
inflammation, such as eosinophilic cationic protein, myeloperoxidase, interleukin-8 (IL-8), 
IL-1beta, tumor necrosis factor alpha and C-reactive protein have also been found into the 
airways and/or blood. In particular, the inhalation of LPS elicits a neutrophilic 
inflammation with IL-8 elevation in both normal and asthmatic subjects (Kharitonov & 
Sjöbring, 2007). 
Future studies with LPS inhalation need to be focused on relevant diagnostic tools for 
detecting the inflammatory reaction in subjects exposed to LPS-containing organic dusts, 
and evaluating whether the large inter-individual variations observed in the response to 
organic dusts or LPS could depend on differences in the molecular mechanisms underlying 
the toxicity of the injuring agent. 
Models of provoked asthma are very valuable tools for understanding the pathobiology of 
asthma, aiding the diagnosis, helping to clarify the mechanisms of actions of effective drugs 
and supporting the development of new drugs. Some provoked models are useful in the 
clinical setting, particularly those that measure direct airway hyper-responsiveness (for 
instance, bronchoconstriction elicited by inhaled methacholine), while others, particularly 
those based on allergen challenge, can be used both in animal models and humans to study 
the mechanisms of allergen-induced airway inflammation and related pathophysiological 
changes, as well as in the development of new drugs for asthma (O’Byrne et al., 2009). In 
particular, investigations on novel bronchoactive drugs in healthy volunteers can be 
accomplished by testing their effects on basal airway calibre and induced 
bronchoconstriction. In this context, gaining further knowledge on the molecular and 
pathophysiological bases of the inflammatory response associated with LPS-induced 
bronchoconstriction is expected to foster the use of this model for investigating new 
antiasthmatic drugs.  
5.3 Biomarkers for immune-allergology drugs 
Allergic rhinitis is a chronic inflammatory disorder of upper airways which evokes 
characteristic signs and symptoms in sensitized individuals exposed to relevant allergens. 
Allergic airway inflammation is characterized by immunoglobulin E (Ig E)-triggered mast 
cells and activated eosinophils, which release pro-inflammatory mediators, such as 
histamine and leukotrienes. Furthermore, allergic rhinitis is associated with elevated serum 
IgE levels and positive skin prick test (SPT) to corresponding allergens. In addition to their 
diagnostic value, serum specific IgE levels and SPT tests may serve as biomarkers to 
monitor the disease activity in response to anti-allergic therapy (Boot et al., 2008). 
Nasal challenge with allergens is a validated, reproducible clinical model for investigating 
the pathophysiology of allergic rhinitis, which also allows the evaluation of kinetics of nasal 
inflammatory responses (Doyle et al., 1995). As such, it may serve as a tool to study the 
effects of anti-allergic interventions, targeting specific inflammatory mechanisms related to 
the upper airway response (de Graaf-in’t Veld et al., 1995). Although nasal biopsies are the 
golden standard for investigating the cellular inflammatory response, there are some 
limitations to this invasive technique (Godthelp et al., 1996): a) it can only be performed by 
an experienced ear-nose-throat physician; b) it provides information just on a limited part of 
upper airways; c) it does not allow repeated sampling within short time intervals (Jacobson 
et al., 1999). By contrast, nasal brushing is a less invasive method, which has emerged as a 
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possible viable alternative for interventional trials requiring repeated sampling. In patients 
with allergic rhinitis, Jacobson et al. (1999) showed that seasonal changes in the number of 
mast cells and eosinophils in nasal brush samples correlated well with those found in nasal 
biopsies. Likewise, intranasal fluticasone produced a similar degree of reduction in these 
inflammatory cells in both brush and biopsy samples. Nasal lavage is another relatively 
non-invasive sampling technique which allows serial assessments of the effects of anti-
inflammatory drugs on soluble factors released by upper airway inflammation (de Graaf-
in’t Veld et al., 1997).  
In the study performed by Boot and colleagues (2008), SPT, serum specific IgE levels and 
inflammatory biomarkers in nasal lavage and material obtained by nasal brushing were 
analyzed in 20 subjects with mild allergic rhinitis, randomly assigned to undergo an 
intranasal challenge with a relevant allergen (n=10) or diluent (n=10), in order to 
simultaneously assess the kinetics of several biomarkers of allergic airway inflammation. 
The authors concluded that serum specific IgE assay and SPT displayed good 
reproducibility in patients with clinically stable allergic rhinitis, and that nasal allergen 
challenge, when used in combination with nasal lavage and brush sampling, is a suitable 
research tool for early drug development. 
5.4 Biomarkers for anticancer drugs 
In oncology, besides toxicity, alternative endpoints have been proposed for early phase trials 
evaluating novel drugs targeted against relevant molecular factors, including the assessment 
of target inhibition in tumours or surrogate tissues, and/or the evaluation of biomarker 
pharmacokinetics (Kelloff et al., 2004; Goulart et al., 2007; Arrondeau et al., 2010). In this 
respect, phase 0 trials can provide critical human PK/PD data to support the design of 
future studies (Kummar et al., 2009). Healthy volunteers, as indicated by international 
guidelines (EMEA, 2004), can be enrolled to perform phase 0 and early phase I trials to 
study new anticancer drugs, evaluating specific surrogate biomarkers of antitumor activity 
and preliminary pharmacokinetics. 
For instance, sunitinib, a thyrosin kinase inhibitor, endowed with antiproliferative and 
antiangiogenic effects, was tested in 12 healthy volunteers at the oral dose of 50 mg for 3–5 
consecutive days in order to perform a preliminary evaluation of its PK/PD profile. The 
parameters assessed in this trial were blood pressure, plasma concentration-time-course of 
sunitinib, its major metabolite SU12662, vascular endothelial growth factors VEGF-A and 
VEGF-C, as well as soluble VEGF receptor-2 (sVEGFR-2). The authors found that the time-
course of blood pressure under treatment with sunitinib was highly consistent with 
published data in patients, while changes in circulating biomarkers were greater in patients, 
as compared with simulations suggested for healthy subjects. Overall, the tumour-
independent pharmacological response to sunitinib in healthy volunteers can be described 
by PK/PD models, thereby facilitating model-based investigations of novel antitumor 
antiangiogenic drugs, using blood pressure and circulating proteins as biomarkers 
(Lindauer et al., 2010).  
Another interesting example of early phase trial on healthy volunteers in oncology is 
represented by the study carried out by Reid et al. (2011). In order to accelerate the clinical 
development of SR13668, an orally active Akt pathway inhibitor, which has demonstrated 
cancer chemopreventive potential in preclinical studies, these authors designed and 
conducted a phase 0 trial for evaluating and comparing the effects of food and 
pharmaceutical formulation on bioavailability of the novel drug. Healthy adult volunteers 
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were randomly assigned to receive a single 38-mg oral dose of SR13668 in one of five 
different formulations, with or without food. Blood samples were obtained pre- and post-
drug administration for pharmacokinetic analyses and the area under the plasma 
concentration-time curve (AUC) was defined as the primary endpoint. Overall, the authors 
found that the AUC values of SR13668 were higher in the fed state and different across the 
formulations. Moreover, they identified a lead formulation of SR13668 for further clinical 
research, supporting the use of phase 0 trials to accelerate the development of new 
anticancer drugs (Reid et al., 2011).  
6. Safety of experimental drugs  
One of the main goals of phase I trials is the gathering of preliminary data on the safety 
profile of new compounds in humans, and also to ensure the safety of enrolled subjects. 
Participation in phase I trials can involve significant risks, and there is no expectance of 
medical benefits, particularly for healthy subjects. Preclinical data must support an 
acceptable level of risk for a new drug given to humans for the first time. On this basis, to 
optimize safety in first-in-man trials, a comprehensive understanding of the new molecule, 
its target, and its expected pharmacokinetics in both normal and pathological tissues is 
required. This concept is particularly important for biopharmaceuticals with slow 
elimination, such as monoclonal antibodies, where the potential for persistent target 
modulation and alteration of downstream cellular processes requires careful assessment 
(Tibbitts et al., 2010). However preclinical toxicology, as testified by several toxic reactions 
observed in early phase trials (Kenter & Cohen, 2006), may not provide suitable information 
on drug safety to predict which potential adverse effects might occur in humans. For this 
reason, adverse reactions must be intensively monitored throughout all early phase studies, 
and first-in-man administration must be conducted in an appropriate pharmacological unit, 
which can rapidly provide intensive cares. Guidelines issued by both American and 
European agencies (EMEA 2007a, 2007b, FDA, 2005, 2009) have been implemented to 
improve the safety of first-in-man trials. In particular, they provide important information to 
investigators and organizations involved in the design and interpretation of preclinical 
programs supporting first-in-man trials. Selecting the first dose to be administered in man 
represents a crucial step for preserving the safety of participants to phase I studies and it 
requires the integration of data provided by multidisciplinary approaches (Tibbitts et al., 
2010). Once sufficient preclinical data are available, the first dose in humans is selected on 
the basis of both relevant toxicological and toxikinetic endpoints, such as the dose not 
eliciting any adverse effect in animals (no observed adverse effect level, NOAEL) and the 
evidence obtained in PK/PD animal models. Moreover, the first dose is calculated by 
application of a safety factor, which takes into consideration the overall robustness and 
quality of preclinical data, as well as the potential for adverse effects in the target population 
(Tibbitts et al., 2010) (Figure 3).  
In March 2006, TGN 1412, a new monoclonal antibody directed against a human 
lymphocytic antigen, which was studied in a first-in-man clinical trial at the Northwick Park 
Hospital of London, caused a catastrophic systemic organ failure in six healthy subjects 
exposed to the new drug (leading to hospitalization of all six volunteers in intensive care 
units), despite being administered at a supposed sub-clinical dose of 0.1 mg per kg, which 
was about 500 times lower than that estimated as safe in animals (Kenter & Cohen, 2006). 
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After the London tragedy, in an attempt of mitigating the risk associated with phase I 
clinical trials, the regulatory agencies, including EMEA, issued new guidelines to aid 
sponsors in the transition from preclinical to early clinical development, including the 
“Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal 
products” (EMEA, 2007a) and “Strategies to identify and mitigate risks for first-in-human 
clinical trials with investigational medicinal products” (EMEA, 2007b). The first guideline 
provides criteria to classify new investigational drugs as potential high-risk medicinal 
products. The second one is intended to assist sponsors in the transition from preclinical to 
early clinical development. These efforts have been collectively gathered under the slogan 
“New Safe Medicines Faster” in Europe and “The Critical Path” in the U.S. (Buoen et al., 
2005). For these reasons, a new procedure, designated as “phase 0,” has been introduced 
into the very early stage of clinical drug development in order to gain early insights into the 
clinical suitability of novel compounds to shorten the duration of phase I studies.  
 
 
Fig. 3. Flow chart for determining starting dose in the first-in-human studies. The 
acquisition of sufficient preclinical data and a suitable safety analysis can allow to obtain the 
human equivalent dose and selecting the starting dose for the first-in-human study 
(Modified from Tibbitts et al., 2010) 
As anticipated above, phase I clinical experimentation encompasses an array of studies, 
which can be performed on healthy volunteers or patients and deal with the determination 
of experimental drug tolerability and its PK/PD profile. In the setting of patients affected by 
a particular disease, these studies can include the evaluation of pharmacodynamic activity, 
mainly for those drugs with a balance between expected therapeutic effect and toxicological 
risk not justifying their administration to healthy subjects. In particular, studies evaluating 
high-risk drugs should be performed in patients when the potential therapeutic effects of 
Starting dose for 
the first-in-human studies 
Safety factor 
Completeness of the preclinical data  
Evauluation of potential adverse effects in the  
intended first-in-human population 
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the test drug are expected to overcome its known toxicity (e.g., antiblastic, anti-HIV drugs) 
or when the expected risks are not acceptable for healthy volunteers. These concepts have 
been widely accepted until recently, when the new “phase 0” or “early phase I” studies 
were introduced, according to which the so-called high risk drugs (e.g., antiblastics, 
antipsychotics, antiepileptics, antiarrhythmics) can be administered to a small number of 
healthy subjects in subtherapeutic micro-dosing studies, with a consequent reduction of 
toxicity risk. Accordingly, phase 0 trials are not intended to replace the traditional dose 
escalation, safety, and tolerability studies, and they cannot indicate whether a candidate 
drug will have a positive impact on the target disease (Schellens, 2009). The scientific 
rationale underlying phase 0 trials includes determining as early as possible whether a new 
drug is capable of modulating the therapeutic target in humans and/or generating 
pharmacokinetic data, such as the biodistribution and metabolism. This early knowledge is 
critical in the process of drug development and it may avoid larger phase I and II trials for 
drugs shown to have unfavorable pharmacologic properties in phase 0 trials (Hill, 2007).  
7. Reimbursement procedures 
The main goal of early phase trials is to gain knowledge about the clinical suitability of 
novel compounds, without pursuing specific therapeutic or diagnostic purposes. As 
anticipated in the previous section, innovative drugs, investigated in these early phases, 
could be harmful to the health of volunteers. Therefore, it is reasonable to assume that 
altruism and idiosyncratic interests alone are unlikely to motivate a sufficient number of 
healthy subjects to act as volunteers in phase I trials. Without payments, recruitment can be 
slow, resulting in a thwarted and unfitting phase I. For these reasons, there is no doubt that 
an adequate remuneration must be offered to subjects recruited in early phase 
investigations. At the same time, coercion and excessive psychological influence should be 
avoided when obtaining consent (Dickert et al., 2002).  
For many years, there has been an ongoing ethical-scientific debate on how to take decisions 
about fair payment of research subjects, viewed as an attempt of compensating them for 
their “lost wages” and “discomfort” due to their participation in clinical trials. As in the U.S. 
and other European countries, in Italy a detailed guideline or a specific law about research 
volunteer reimbursement is still lacking (Pasqualetti et al., 2010).  
Dickert et al. (2002) reported that only 37.5% of clinical research organizations included in their 
analyses (academic research centers, pharmaceutical companies, contract research 
organizations, and independent institutional review boards) had written guidelines about the 
payment of healthy subjects. These organizations disclosed that investigators and IRBs make 
decisions about payments and that in some studies both healthy and ill subjects are paid for 
reimbursement of their time, inconvenience, and travel, as an incentive, or for incurring risk. 
Dickert et al. (2002) underlined also some methods adopted by different organizations to 
establish “how to pay” by specific formulas: payment for time by the hour, payment per 
inpatient day or outpatient visit, payment by a flat rate per day or visit, supplemental payment 
for the “inconvenience” associated with certain procedures. Overall, most organizations 
require that the estimated payment must be delivered to subjects as prorated (i.e., fractional 
payment based on the amount of time or procedures actually accomplished) rather than as a 
contingent payment at the completion of the study (Iltis, 2009).  
Several authors support the opportunity of a reimbursement to healthy volunteers and 
propose different hypotheses to resolve this issue (Pasqualetti et al, 2010). Among the 
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proposed ways, those indicated by Iltis (2009) and Resnick (2008) appear to be quite 
interesting. Iltis (2009) underlines the conflict existing between the practice of providing 
appropriate payments, thus avoiding undue influence, and the requirements of justice when 
recruiting normal healthy volunteers for phase I clinical trials. By keeping payments low 
intentionally, in line with recommendations by IRBs, investigators might target or 
systematically recruit healthy subjects from lower socio-economic levels, thus not fulfilling 
criteria of social justice. On the other hand, higher reimbursements to volunteers might 
prompt more persons to enter clinical studies, while not discouraging the less well-off from 
enrollment. Although investigators would likely prefer to achieve the goal of having a 
sufficient number of subjects within a reasonable time-frame, the latter method might 
appear as a wrong influencing procedure for the recruitment of research volunteers.  
An alternative way to decrease or increase payments homogeneously is to offer 
reimbursements based on various and personalized contributions, which may differ 
according to the specific procedures required by trial protocols (Iltis, 2009). Resnick (2008) 
describes five distinct models of payments to research subjects: (1) free market model: 
subjects are paid for providing services (such as completing surveys and undergoing tests 
and procedures), goods (such as blood, tissue or other biological samples), and to cover 
potential risks; (2) wage payment model: participants earn a wage equivalent to that of a 
typical unskilled labourer; (3) reimbursement model: in this setting, participation in clinical 
research is regarded as a public service (altruism) and volunteers can be paid for their travel 
expenses, lost wages, baby sitting expenses, etc.; (4) appreciation model: subjects are not 
compensated for the costs of participation, but they receive money or gifts, such as t-shirts, 
mugs, gift certificates, as a sign of the investigators’ appreciation; (5) fair benefits model: 
subjects are neither paid labourers nor paid volunteers, but partners in research, sharing the 
benefits of research, including the economic ones.  
The first two models represent a form of “compensated labour” and could motivate 
individuals to take part in a clinical trial merely to obtain consistent gains. By contrast, the 
remaining models reflect a “free and voluntary contribution” to community, but they can’t 
embrace the actual motivations of healthy volunteers, who might be seeking free clinical 
tests or monetary gain (Resnick, 2008).  
The lack of international and local guidelines about some crucial aspects related to the 
recruitment of healthy volunteers in early phase clinical trials, such as the definition of 
healthy status, payments, advertisement, and participation of the same subject in different 
experimentations, stimulated a proposal by the Centre for Clinical Drug Experimentation of 
Pisa University Hospital to implement specific operative procedures (Pasqualetti et al., 
2010), attempting to properly address the following issues: (1) advertising to healthy 
volunteers for recruitment in early phase clinical trials after approval by the local ethics 
Committee; (2) evaluation of the clinical and psychological status of a potential healthy 
volunteer; (3) creation of a database containing information on selected healthy subjects to 
be contacted for possible enrollment in a clinical trial, and allowing a proper monitoring of 
their participation in different experiments; (4) calculation of adequate reimbursements to 
healthy volunteers participating to clinical trials. The latter operative procedure is based on 
criteria which, although not yet fully comprehensive, provide a useful frame to estimate the 
amount of fair payment to healthy volunteers. In particular, it encompasses a number of 
items for which the amount of specific reimbursement is indicated, including the number of 
blood samples, peripheral venous catheter or needle placement, number of clinical 
laboratory analyses performed during the screening and follow-up (blood and urine 
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sampling, ECG, psychopathological test administration); other biological fluid sampling; 
restrictions imposed by a specific study protocol (for example, smoking and alcohol ban, 
physical exercise, etc.); investigational drug administration route (invasive: intramuscular, 
intravenous, by naso-gastric tube; not invasive: oral); filling in questionnaires and diaries; 
time spent at the clinical pharmacology centre (per hour); discomfort or distress caused by 
study procedures (classified as minor, moderate and major).  
8. Conclusion 
Drug experimentation in healthy volunteers is aimed at investigating pharmacokinetics and 
pharmacodynamics as well as documenting safety and tolerability of new compounds. 
Therefore, strategies to evaluate risks versus benefits during phase I and phase II clinical 
studies need to be refined continuously to improve efficiency and quality. At the same time, 
there is a clear need to better predict inter-subject variability, off-target toxicity, clinical 
outcomes and disease pathophysiology (Cohen, 2006). 
Since drug development is a complex, costly and risky process, evidence has now been 
accumulated concerning the promising role of imaging in highlighting risks and costs 
associated with clinical drug experimentation by validating targets, confirming mechanisms of 
action, obtaining early markers of pharmacological activity, assessing pharmacokinetic profiles 
and providing prognostic indicators. Despite these interesting promises, consideration must be 
given to the possibility of confounding factors, which could mislead surrogate endpoints, and 
the extent to which biomarkers are validated for their intended purposes. 
The issue of validation of new imaging biomarkers needs to be addressed in a more 
systematic and rigorous way, including the search for correlations among imaging and 
molecular biomarkers, elucidating the relationships between particular imaging biomarkers 
and the purported pathophysiological pathways. With recent advances in genomic, 
proteomic imaging and computational sciences, pharmaco-imaging is gaining an important 
role in drug development (Bakthiar, 2007). 
Other critical aspects of drug experimentation in healthy volunteers include both legislative 
and ethical issues, pending the lack of international guidelines suggesting specific procedures 
for the recruitment and reimbursement of healthy subjects enrolled in clinical studies. 
In order to clarify the main unresolved questions, the international scientific community 
needs to address and resolve urgently the following points: a) international definition of 
healthy status based on standard physical, psychological and clinical parameters; b) 
appropriate advertisement addressed to potential participants to first-in-man clinical trials; 
c) international standard criteria for offering fair payments to healthy volunteers enrolled in 
phase I trials; d) need of a national register, following the examples of some Countries 
(Resnik & Koski, 2011), in order to monitor the participation of healthy subjects and avoid 
their simultaneous enrollment in early clinical trials at the same or other centre for drug 
experimentation. 
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